|
Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company focuses on developing gene therapy treatments for oncology and neurotherapy. Its lead product,TroVax, is in testing for renal and colorectal cancer and is designed to stimulate the body's immune response to attack tumor cells. Another leading candidate, ProSavin, is in testing for treatment of Parkinson's disease. The company has several additional products in various stages of clinical development. Oxford BioMedica has awarded Sanofi-Aventis exclusive rights to develop and commercialize TroVax globally. The company's California-based BioMedica subsidiary handles its business development in North America and Asia.
|
| | | Contact Information | |
Address: |
Medawar Centre, Robert Robinson Ave., The Oxford Science Park
Oxford OX4 4GA, United Kingdom
| | Phone: | +44-186-578-3000 | | Fax: | +44-1865-783-001 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 26.60 M | | Revenue Growth (1 yr): | 84.70% |
|
|
Key People
| | • |
Chairman:
Prof Alan Kingsman
| | • |
CEO and Director:
John Dawson
| | • |
CFO and Director:
Andrew B. Wood
|
|
|
